Buyout includes $51.9 million payout to Synthes' top executive

12/5/2011 | MassDevice.com (Boston)

Michel Orsinger, CEO of Synthes, will receive a $51.9 million payout as part of a $21.3 billion acquisition by Johnson & Johnson. The buyout, which is expected to be completed early next year, will allow Johnson & Johnson to add Synthes to its DePuy unit, with Orsinger taking over as head of the company's new global orthopedics team.

View Full Article in:

MassDevice.com (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC